Medindia
Medindia LOGIN REGISTER
Advertisement

Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation

Wednesday, February 6, 2008 General News
Advertisement
SOUTH SAN FRANCISCO, Calif., Feb. 5 Anesiva,Inc. (Nasdaq: ANSV) will announce financial results for the fourth quarter andyear ended 2007 after the markets close on Monday, February 11, 2007 and willhold a webcast teleconference at 4:30 p.m. EDT that day. Members of Anesiva'smanagement team will discuss financial results from the fourth quarter andfull year 2007 as well as provide an overview of the company's productpipeline, recent events and milestones.
Advertisement

Interested parties can listen to the live audio webcast by dialing(800) 340-6289 (international dial: (706) 634-1538) or by logging on tohttp://www.anesiva.com and going to the Investor Information page. For thoseunable to participate via the Internet, a 24-hour replay will be available forseven days after the call by dialing (800) 642-1687 (international dial:706-645-9291) and giving the following pass code: 31729950. The webcast willbe available until the company's next quarterly financial results conferencecall.
Advertisement

Anesiva further announced that company management will present at thefollowing events in February 2008:

-- BIO CEO & Investor Conference

Feb. 13, 2008 1:15 p.m. Eastern Time

Presentation:

http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ANSV&item_id=1752218

Live audio webcasts of the presentations will also be available online viathe Investor Relations portion of Anesiva's website at http://www.anesiva.com.Please connect to Anesiva's website several minutes prior to the start of thewebcast to ensure adequate time for any software download that may benecessary.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to bethe leader in the development and commercialization of novel pharmaceuticalproducts for pain management. The company has one FDA-approved product,Zingo(TM), for the reduction of pain associated with peripheral venous accessprocedures in children ages three to 18. The second product in Anesiva'spipeline, Adlea(TM), has been shown to reduce pain after only a singleadministration for weeks to months in multiple settings in numerous mid-stageclinical trials for site-specific, acute and chronic, moderate-to-severe pain.Anesiva is based in South San Francisco, CA. For more information aboutAnesiva's leadership in the development of products for pain management, andan overview of the clinical challenges being addressed by its productcandidates, go to http://www.anesiva.com.-- Roth Capital Partners 20th Annual Growth Stock Conference Feb. 21, 2008 9 a.m. Pacific Time Presentation: http://www.rothcp.com/main/Page.aspx?PageID=7010

SOURCE Anesiva, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close